港股異動 | 四環醫藥(0460.HK)高開3.36% 斥資2667.41萬港元回購1000萬股
格隆匯5月10日丨四環醫藥(0460.HK)高開3.36%,報2.77港元,最新總市值262億港元。四環醫藥上週五(7日)晚間發公吿稱,2021年5月7日耗資2667.41萬港元回購1000萬股,回購價格每股2.63-2.70港元。董事會相信股份回購反映公司對其業務的長遠前景充滿信心,符合公司及公司股東的整體利益。據悉,四環醫藥是國內特色心腦血管領域製藥企業,公司於2014年起將業務拓展至醫美領域,通過與韓國Hugel公司進行戰略合作實現其肉毒素產品在國內的獨家代理,並於2020年實現重磅產品樂提葆在國內的獲批上市。今年以來醫美概念股和抗疫概念股均大漲,四環醫藥今年迄今已累漲近2.4倍。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.